Company secures funding to fuel expansion of its Thoraguard® System; adds veteran medtech leader Timothy Still to Board of Directors
Centese, Inc., a leader in digital surgery technology, announces the successful closing of its $15M Series B funding round. The round, led by Medical Technology Venture Partners with participation from new and existing investors, will fund commercialization efforts, advance clinical initiatives, and bolster advanced product development of the Thoraguard Intelligent Chest Tube Management System.
“This Series B funding marks an exciting milestone for Centese,” said Evan Luxon, CEO of Centese, Inc. “This investment not only validates the rapid adoption of digital technology in surgery but will accelerate our mission to transform the recovery process for as many heart and lung surgery patients as possible.”
The Thoraguard System, recognized for its innovative solution to improve post-operative care in cardiac and thoracic surgery, has been validated in peer-reviewed clinical studies demonstrating superiority over legacy products. These studies, including those conducted at world-class institutions like Stanford University Medical Center and NYU Langone Health, have highlighted Thoraguard’s ability to shorten hospital stays, automate care, and provide superior monitoring of critical patient parameters.
In a strategic move to strengthen its leadership for this next phase, Centese, Inc. is also excited to announce the appointment of Timothy Still to its Board of Directors. Mr. Still, an accomplished CEO and Board Member, brings over three decades of experience leading organizations commercializing disruptive medical technologies in the areas of in vitro diagnostics, life science tools, medical devices, and digital health.
“Tim’s extensive experience and proven track record leading medtech organizations will be a tremendous asset as we transition Centese into our next phase of growth,” said Mr. Luxon. “His experience in commercial growth strategy, operational expansion, and M&A is well-aligned with our strategic goals.”
Mr. Still commented, “I am thrilled to join Centese at such a transformative time. The potential for the Thoraguard System to redefine post-operative care is enormous, and I look forward to contributing to the company’s growth and success.”
About Centese
Centese, Inc. is driven to safeguard patients, improve outcomes, and reduce costs in cardiothoracic surgery. Inspired to overcome the limitations of conventional analog chest tubes for postoperative drainage, the company envisioned a digital solution and developed the first smart, automated chest tube and drainage management system.The Thoraguard Intelligent Chest Tube Management System combines innovative design with intelligent software to help patients recover faster, enhance clinical decision making with reliable data, and enable patient care teams to streamline their workflow.
###